Nightingale
Research
Trials
Now
Now
Recruiting
Effect of Muvalaplin tablet on the reduction of major adverse cardiovascular events in adults with elevated Lipoprotein(a), who have had a prior atherosclerotic cardiovascular event, or are at risk for a first atherosclerotic cardiovascular event.
- Age > 18 years
- Lp(a) blood test taken at pre-screening or screening visit
- Oral tablet taken daily
- History of coronary artery disease (heart attack, bypass grafts or stroke) OR
- History of peripheral artery disease (amputation, stents in legs) OR
- At risk of having a coronary or peripheral arterial event (need to have 4 risk factors)
History of Heart Attack, Stroke or Kidney Disease with Overweight
Adelaide SA | Frankston VIC
Effect of a new medication on patients with established CVD and/or CKD and obesity.
- Age > 50 years
- BMI > 25 kg/m²
- Oral tablet daily
- Not taking Ozempic/Mounjaro
- History of heart attack or coronary artery disease OR
- History of stroke OR
- History of peripheral vascular disease OR
- History of chronic kidney disease
Fatty Liver Disease and Overweight
Adelaide SA
A study to investigate the effect of a new medication in adults with Fatty Liver Disease and Obesity who are at risk of developing worsening liver disease.
- Age > 18 years
- BMI ≥ 25kg/m2
- Not taking Ozempic/Mounjaro
- Weekly self-injection
- Elevated Liver Fat content - assessed at screening
- No history of surgical treatment for obesity (some exceptions)
- Not diabetic type 1
Heart Disease, Diabetes and High Blood Pressure Study
Adelaide SA | Frankston VIC
A study to test a new medication in combination with Empagliflozin (a currently available medication) in people with Type 2 Diabetes, high blood pressure and cardiovascular disease.
- Age > 18 years
- History of heart attack, stroke or vascular disease AND high blood pressure
- One additional risk factor for developing heart failure (assessed at screening)
- Diabetic or non-diabetic
- Oral tablet daily
Symptomatic Heart Failure Study
Frankston VIC
Effect of a new medication in combination with Empagliflozin (medication available currently) in patients with HF and EF>40%.
- Age > 18 years
- Elevated heart failure bloods (tested at screening visit)
- Taking diuretic medication
- Oral tablet daily
Chronic Kidney Disease and High Blood Pressure Study
Adelaide SA | Goolwa SA
A study to assess the effectiveness of a new medication in combinatinon with Dapagliflozin (a currently available medication) in people with Chronic Kidney Disease and High Blood Pressure.
- Age > 18 years
- Reduced kidney function (assesed by a blood test at screening)
- Taking regular blood pressure medication
- Blood pressure remains high despite medication
Upcoming Trials
▼
Adelaide SA | Frankston VIC
A research study looking at a new medication for people with Heart Failure and Obesity.
- Age > 18 years
- BMI ≥ 30kg/m2
Adelaide SA
Efficacy and Safety of a new medication in Participants with Obstructive Sleep Apnea and Obesity or Overweight who are not diabetic
- Age > 18 years
- Known moderate to severe OSA (free repeat sleep study during screening)
Adelaide SA
A research study investigation how well a new medication helps people with excess body weight and obstructive sleep aponea treated with CPAP machines to lose weight and improve the sleep aponea.
- Age > 18 years
- BMI > 27kg/m2
Adelaide SA
A research study investigating a new medication to see how it helps people with excess body weight and Obstructive Sleep Aponea not using CPAP lose weight and improve the sleep aponea
- Age > 18 years
- Overweight - BMI
Ongoing Trials
(Enrolment Closed)
▼
Adelaide SA | Goolwa SA
Effect of a new medication on participants without type 2 diabetes who have obesity and OSA.
- BMI > 27 kg/m²
- Type 2 diabetes
Adelaide SA | Goolwa SA
Effect of a new medication on participants with CVD and/or CKD.
- BMI > 27
- Established CKD and/or CVD
Adelaide SA | Goolwa SA
Effect of a new medication on participants without type 2 diabetes who have obesity and knee OA.
- BMI > 30 kg/m²
- Weight-related comorbidities: hypertension, high cholesterol, knee pain / osteoarthritis
Adelaide SA | Goolwa SA
Trialling a new medication on elevated Lp(a) in people with CVD or at risk of CVD.
- Age < 55 years
- Individuals at risk for a first cardiovascular (CV) event, as determined at screening
Completed Trials
▼
Adelaide SA | Goolwa SA
Effect of a new medication on participants with or without type 2 diabetes who have obesity.
- BMI > 35 kg/m²
- Diabetic or non-diabetic
Adelaide SA | Goolwa SA
Effect of Tirzapetide vs Dulaglutide on CV events in patients with Type 2 Diabetes.
- Age > 40 years
- BMI > 25 kg/m²
